Fairvalue-Calculator Fairvalue-Calculator
EN DE

Caribou Biosciences, Inc (CRBU) Fair Value & Analysis

Healthcare · US · Market cap $163M

Price$1.66
Fair Value$0.9300
Upside-44.0%
Quality95/100
Evidence: Low Range $0.6100 – $1.16

Fair value as of: Jun 25, 2026

Analysis

Caribou Biosciences, Inc (CRBU) currently trades at $1.66, while our model-based Fair Value estimate is $0.9300 — implying the stock looks roughly 44.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Caribou Biosciences, Inc (CRBU) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.9300 versus a price of $1.66 — about −44% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CRBU?
Our 21-model fair value for Caribou Biosciences, Inc is $0.9300 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.66.
What is the quality score of CRBU?
Caribou Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.